Theranos today announced that a key role has been filled on the company’s executive team, with the arrival of Cass Grandone as Senior Vice President of Product Development. Mr. Grandone’s career has included R&D roles of increasing responsibility, including leading the delivery of Abbott’s multi-billion dollar ARCHITECT and Accelerator diagnostic platforms.
“Cass brings a passion for healthcare along with considerable experience in launching global diagnostic platforms that save and improve lives,” said Theranos CEO Elizabeth Holmes. “His leadership will be critical to helping Theranos realize its longstanding mission to make lab testing more accessible.”
“I was drawn to Theranos by the unique potential of the miniLab to provide comprehensive lab services during a single patient visit,” said Mr. Grandone. “Now that I am here, I look forward to helping Theranos deliver on its promise as a pioneer in the diagnostics industry.”
Mr. Grandone began at Abbott Diagnostics in design and systems engineering, eventually becoming Divisional Vice President of Core Lab Assays & Systems Product Development and leading Abbott’s next generation “ci” Core Lab and “s” Transfusion AlinityTM platforms. He has deep experience bringing products through FDA approval and, while at Abbott, implemented company-wide modernization of R&D portfolio governance, design control frameworks and statistical support automation. Most recently, Mr. Grandone was Vice President Global Infusion Systems R&D at Hospira, a Pfizer company. He holds a BS in Mechanical Engineering from the University of Illinois-Champaign/Urbana.
Founded in 2003 by Elizabeth Holmes, Theranos, Inc. is a health technology company headquartered in Palo Alto, Calif. Its proprietary miniLab platform is designed to enable earlier disease detection and intervention by facilitating small-sample collection, testing and rapid communication of diagnostic information in distributed settings. To learn more about Theranos, visit www.theranos.com.